Routine test markers include phosphorylated VEGFR2, higher baseline TILs or a greater increase in tumor-infiltrating CD8+ T cells during therapy, lower baseline plasma HGF/IL-8, a decrease in plasma IL-8, an increase in plasma TIM-3/CD152 during therapy, higher baseline CD4+ T-cell or B-cell proportion in blood, leukopenia, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, prognostic nutritional index, clinical-radiomics nomograms, adipose tissue area, neutrophil-to-lymphocyte ratio, and carbohydrate antigen 19–9. This evidence concerns the gene CD4 and neoplasm.